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A locus for inherited focal segmental glomerulosclerosis maps to
chromosome 19q13. Rapid Communication. We performed a genome-wide
linkage analysis search for a genetic locus responsible for kidney dysfunc-
tion in a large family. This inherited condition, characterized by protein-
uria, progressive renal insufficiency, and focal segmental glomeruloscle-
rosis, follows autosomal dominant inheritance. We show with a high
degree of certainty (maximum 2-point lod score 12.28) that the gene
responsible for this condition is located on chromosome 19q13.
Focal segmental glomerulosclerosis (FSGS) represents a patho-
logic finding in several renal disorders characterized by protein-
uria and progressive decline in renal function. Focal segmental
glomerulosclerosis occurs in primary (idiopathic) and secondary
forms. Observers are increasingly aware of possible genetic con-
tributions to the development of FSGS, and it has been reported
in multiple families and sibling pairs [1–4]. Both dominant and
recessive forms may exist [1]. Investigators have also noted
possible associations between particular HLA alleles and FSGS
[5, 6]. FSGS often occurs secondary to other conditions, including
conditions with a clear or suspected genetic component such as
obesity, Alport’s syndrome, and oligomeganephronia [7], raising
the possibility that genes involved in inherited forms of FSGS may
also be involved in more common causes of FSGS-like secondary
renal disease.
As an initial step towards identification of genes involved in the
pathogenesis of inherited FSGS, we performed linkage analysis to
map the disease gene in a large family with this condition. We
show that the FSGS gene in a large family with autosomal
dominant inheritance of this condition maps to a region of
chromosome 19q13.
METHODS
Clinical studies
The study family, previously identified by B.J.M. and K.E.C. [8],
was clinically re-evaluated. At the time of evaluation, a peripheral
blood sample was obtained for establishment of lymphoblastoid
cell lines, DNA extraction, and serum creatinine measurements.
Genotypes were ascertained without knowledge of clinical status.
Serum creatinine, urine protein, and urine creatinine were mea-
sured by the Brigham and Women’s Hospital clinical laboratory.
Measurement of urine microalbumin was performed by Nichols
Laboratories. Studies were performed after obtaining informed
consent in accordance with a protocol approved by the Human
Research Committee of the Brigham and Women’s Hospital.
DNA analyses
Genomic DNA was extracted from peripheral blood using the
SDS-proteinase K method [9]. For the initial genome screen,
polymorphic markers were chosen from the Weber 6A set [10].
Short tandem repeat markers within these loci were analyzed by
PCR with one end-labeled primer and gel electrophoresis [9].
Other markers used in the chromosome 19q1 region are from the
Genethon mapping panel [11], or, in the case of D19S608,
D19S609, and D19S610, from reference [12]. Genotyping was
performed precisely as described previously [13] without knowl-
edge of clinical status.
Statistical analyses
Two-point linkage analyses were performed using the MLINK
computer program [14, 15]. Logarithm of odds (lod) scores were
calculated assuming a disease penetrance of 0.95. Allele frequen-
cies were assumed to be 1/N, where N is the number of alleles for
a given marker.
RESULTS
Clinical evaluations
A detailed clinical description of this family has been published
previously [8]. We re-evaluated all available family members by
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measuring serum creatinine, urine protein, and urine microalbu-
min excretion. Twenty-four-hour urine protein excretion was
estimated from a spot urine protein to creatinine ratio [16]. The
pedigree appears in Figure 1 and the chromosome 19 ideogram is
shown in Figure 2. An individual was considered affected if he/she
had (1) renal biopsy evidence of FSGS; (2) end-stage renal disease
without another cause; or (3) elevated urine microalbumin excre-
tion without another cause (microalbumin . 20 mg/g creatinine).
An individual was considered indeterminate if he/she had ele-
vated urine albumin excretion in a random urine sample but
another possible cause (such as diabetes). An individual was
considered unaffected if he/she had no microalbuminuria. Indi-
viduals under the age of 18 were not included in this analysis.
The renal biopsy from individual IV-18 is shown in Figure 3.
Biopsies from individuals III-14 and III-36 were originally read as
diffuse glomerulosclerosis and membranous nephropathy, respec-
tively. However, review of biopsy III-36 showed glomeruli with
focal and segmental sclerosing lesions and no subepithelial or
intramembranous electron-dense deposits were seen by electron
microscopy, suggesting that this individual in fact had FSGS.
Biopsy III-14 was not available for review.
Variable expression of the gene defect in this family was
demonstrated by the fact that, whereas some family members
developed ESRD by the fourth decade or had severe proteinuria,
others demonstrated only mild microalbuminuria, including one
individual whose two daughters were severely affected (individual
III-29).
Genetic analysis
All of the family members in this study were genotyped using
160 polymorphic genetic markers from the CHLC markers (We-
ber set 6) spaced throughout the genome [10]. Sufficient informa-
tion was typically obtained to exclude linkage within 10 to 20
centiMorgans (cM) flanking each locus (lod score , 22). Analysis
of marker D19S589 suggested that the disease gene might be
located on chromosome 19. The maximum two point lod score
with D19S589 was 1.63 at u 5 0.25. To clarify the location of the
disease locus, analyses were performed with other loci from
Fig. 1. The pedigree of a large kindred with inherited nephropathy. Individuals with end-stage renal disease are labeled ESRD. Below the symbols of
individuals classified as affected are urine protein measurements, either urine microalbumin (expressed as mg microalbumin per gram creatinine)
indicated by “m5” or, total protein in grams per day as estimated by spot urine/creatinine ratio. Asterisks indicate individuals who have undergone renal
biopsy. Urine microalbumin values are also indicated for individuals III-1, and V-1, both of whom carry the disease allele but neither of whom has
increased microalbumin excretion.
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chromosome 19q (Table 1). Among affected individuals, no
recombinants were seen between kidney dysfunction and all loci
examined in the region between D19S213 and D19S417. Two
point lod scores between disease and these loci in this region were
all highly significant (Table 1). The maximum two point lod score
was 12.28 at D19S191 at genetic distance u 5 0.0, equivalent to a
less than 1 in 1012 chance that the cosegregation of D19S191
alleles and nephropathy was a chance association. Although these
calculations were performed using allele frequencies of 1/N,
where N is the number of alleles, the result was insensitive to
changes in allele frequencies. We also calculated lod scores
excluding the individuals whose diagnoses are most likely to be in
error (because of either non-penetrance or proteinuria of another
cause). If all clinically unaffected individuals are excluded, then
Fig. 2. Chromosome 19 ideogram. Shown is a linear representation of recombination events occurring in the study family. Open bars represent the
disease-associated haplotype. Closed bars represent a non disease-associated haplotype. Individuals III-1 and V-1 are clinically unaffected but carry the
disease allele; these individuals are presumed to be examples of non-penetrance. Recombination events in affected individuals place the disease gene
interval within the region flanked by loci D19S213 and D19S223. The physical distances indicated to the left of the ideogram are in accordance with the
Lawrence Livermore National Laboratory chromosome 19 data.
Table 1. Pairwise lod scores reflecting linkage between chromosome 19 loci and a focal segmental glomerulosclerosis locus
Locus
Recombination fraction (u)
0.00 0.01 0.05 0.10 0.15 0.20 0.30 0.40
D19S414 27.44 24.14 21.51 20.11 0.63 1.01 1.11 0.68
D19S714 22.59 22.29 20.81 0.62 1.53 1.99 2.01 1.25
D19S222 0.97 3.04 4.28 4.61 4.52 4.20 3.12 1.62
D19S213 23.09 21.79 20.64 0.59 1.21 1.47 1.49 0.75
D19S425 7.61 8.70 9.19 8.87 8.21 7.34 5.17 2.54
D19S208 8.54 8.53 8.22 7.60 6.83 5.98 4.04 1.91
D19S609 6.12 6.07 5.76 5.24 4.66 4.03 2.66 1.16
D19S610 7.38 7.31 6.94 6.32 5.61 4.85 3.24 1.53
D19S608 8.42 10.63 10.94 10.43 9.59 8.55 6.04 3.05
D19S191 12.28 12.19 11.66 10.73 9.64 8.43 5.73 2.77
D19S224 2.52 4.98 6.04 6.15 5.83 5.28 3.76 1.82
D19S220 7.75 7.70 7.34 6.77 6.10 5.35 3.68 1.82
D19S228 3.61 6.30 6.43 5.99 5.40 4.73 3.23 1.56
D19S417 7.17 7.11 6.76 6.20 5.55 4.85 3.28 1.55
D19S223 3.99 9.59 10.06 9.69 8.96 8.02 5.71 2.90
D19S420 0.34 6.64 8.55 8.77 8.37 7.65 5.59 2.91
D19S589 213.79 24.07 21.09 0.53 1.30 1.61 1.45 0.78
Lod scores were calculated at various recombination fractions as described in the Methods section.
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the lod score at u 5 0.0 is 7.44; if those individuals with urine
albumin excretion less than 500 mg/g creatinine are excluded as
well, the lod score at u 5 0.0 is 5.41.
Haplotype analysis defined recombinant events between D19S213
and D19S425 in two affected individuals, between D19S222 and
D19S213 in two affected individuals, between D19S223 and D19S420
in one affected individual, and between D19S420 and D19S223 in
one affected individual. Recombinant events in two clinically
unaffected individuals were also observed (Fig. 2). These recom-
binant events suggest that the gene defect responsible for mi-
croalbuminuria and FSGS in this family is located in the 7 Mb
region between D19S223 and D19S213.
DISCUSSION
We have presented evidence that the gene for renal disease in
a large pedigree is located within an approximately 7 centiMorgan
region on chromosome 19. Of particular interest is the fact that
this region includes the 1Mb region harboring the gene for
congenital nephrotic syndrome of the Finnish type (CNF) [17, 18].
Thus, it is a plausible hypothesis that these two very distinct forms
of nephrotic syndrome and kidney failure may represent different
mutations in the same gene. The region of chromosome 19 we
have defined is syntenic to a portion of mouse chromosome 7 [19].
We are unaware of any mouse mutants with FSGS-like pheno-
types that are the result of genetic defects in this region.
Recombination events suggest that this FSGS region is flanked
by loci D19S223 and D19S213. It is possible that this precise
location is incorrect if the diagnoses of some individuals with
these critical crossovers are incorrect if, for example, the affected
individuals have proteinuria from another cause, or the unaf-
fected individuals have the disease allele but are non-penetrant.
We feel this is unlikely, however, as these conclusions are based
on crossovers observed in several individuals. The extremely high
lod scores that persist even when all those individuals with the
least certain diagnoses are excluded from the analysis make it
certain that the disease gene is located in or near this region.
Individuals III-1 and V-1, who are both clinically unaffected, carry
the disease-associated haplotype over the entire region of chro-
mosome 19 indicated, and they are presumed to be examples of
non-penetrance.
It is important to emphasize the great variability in the pheno-
typic expression of the disease gene. Although we have termed the
pathologic condition in this family inherited FSGS, this may be
misleading. Some family members carrying the FSGS allele
exhibit end-stage renal failure at a relatively young age, whereas
others show only microalbuminuria, or in the case of individuals
III-1 and V-1, no abnormalities at all. This suggests that there are
other factors involved in the pathogenesis of renal failure in these
patients. These factors may be genetic, environmental, or both.
Focal segmental glomerulosclerosis is seen not typically ob-
served as an inherited entity; much more frequently it presents as
an idiopathic lesion or as a consequence of other underlying
disease such as intravenous drug use, vesico-ureteral reflux, or
HIV infection. This raises the possibility that this FSGS gene may
also be involved in the susceptibility to so-called secondary renal
disease. It should now be possible for investigators studying genes
involved in renal failure progression (for example, from diabetes)
to test this hypothesis utilizing genetic markers in this region. It
remains to be determined in other families with inherited FSGS
whether the disease gene maps to this same locus, or, alterna-
tively, if familial FSGS is genetically heterogeneous. Patients with
idiopathic (primary) FSGS may also have a genetic disease: some
fraction of patients with primary FSGS may in fact have sporadic
mutations in this (or another) FSGS gene. Testing this hypothesis
will await identification of the FSGS gene(s).
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